Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Coghill

Showing results (201-210 of 230) with videos related to

Pageof 23
Sort By:
Neuroscience and Biobehavioral Reviews|October 20, 2020
Long term methylphenidate exposure and growth in children and adolescents with ADHD. A systematic review and meta-analysisSara Carucci, Carla Balia, Antonella Gagliano, et al.
The Lancet. Psychiatry|March 23, 2023
Long-term safety of methylphenidate in children and adolescents with ADHD: 2-year outcomes of the Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE) studyKenneth K C Man, Alexander Häge, Tobias Banaschewski, et al.
European Child & Adolescent Psychiatry|November 1, 2017
A comparison of the clinical effectiveness and cost of specialised individually delivered parent training for preschool attention-deficit/hyperactivity disorder and a generic, group-based programme: a multi-centre, randomised controlled trial of the New Forest Parenting Programme versus Incredible YearsEdmund J S Sonuga-Barke, Joanne Barton, David Daley, et al.
Journal of Attention Disorders|February 23, 2024
Methylphenidate and Sleep Difficulties in Children and Adolescents With ADHD: Results From the 2-Year Naturalistic Pharmacovigilance ADDUCE StudyAlexander Häge, Kenneth K C Man, Sarah K Inglis, et al.
Journal of Attention Disorders|December 17, 2020
Physical Health, Media Use, and Mental Health in Children and Adolescents With ADHD During the COVID-19 Pandemic in AustraliaEmma Sciberras, Pooja Patel, Mark A Stokes, et al.
Frontiers in Behavioral Neuroscience|July 25, 2022
Toward Precision Medicine in ADHDJan Buitelaar, Sven Bölte, Daniel Brandeis, et al.
The Lancet. Child & Adolescent Health|April 21, 2020
ADHD management during the COVID-19 pandemic: guidance from the European ADHD Guidelines GroupSamuele Cortese, Philip Asherson, Edmund Sonuga-Barke, et al.
Journal of Attention Disorders|December 17, 2019
Cognition, ADHD Symptoms, and Functional Impairment in Children and Adolescents With Neurofibromatosis Type 1Jonathan M Payne, Kristina M Haebich, Rachel MacKenzie, et al.
European Child & Adolescent Psychiatry|December 17, 2013
Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challengesJeffrey Glennon, Diane Purper-Ouakil, Mireille Bakker, et al.
Molecular Autism|July 2, 2026
Autism in neurofibromatosis type 1: prevalence, phenotype and clinical implicationsJonathan M Payne, Kristina M Haebich, Anita K Chisholm, et al.
Pageof 23

Showing results (201-210 of 230) with videos related to

Sort By:
Pageof 23
Neuroscience and Biobehavioral Reviews|October 20, 2020
Long term methylphenidate exposure and growth in children and adolescents with ADHD. A systematic review and meta-analysisSara Carucci, Carla Balia, Antonella Gagliano, et al.
The Lancet. Psychiatry|March 23, 2023
Long-term safety of methylphenidate in children and adolescents with ADHD: 2-year outcomes of the Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE) studyKenneth K C Man, Alexander Häge, Tobias Banaschewski, et al.
European Child & Adolescent Psychiatry|November 1, 2017
A comparison of the clinical effectiveness and cost of specialised individually delivered parent training for preschool attention-deficit/hyperactivity disorder and a generic, group-based programme: a multi-centre, randomised controlled trial of the New Forest Parenting Programme versus Incredible YearsEdmund J S Sonuga-Barke, Joanne Barton, David Daley, et al.
Journal of Attention Disorders|February 23, 2024
Methylphenidate and Sleep Difficulties in Children and Adolescents With ADHD: Results From the 2-Year Naturalistic Pharmacovigilance ADDUCE StudyAlexander Häge, Kenneth K C Man, Sarah K Inglis, et al.
Journal of Attention Disorders|December 17, 2020
Physical Health, Media Use, and Mental Health in Children and Adolescents With ADHD During the COVID-19 Pandemic in AustraliaEmma Sciberras, Pooja Patel, Mark A Stokes, et al.
Frontiers in Behavioral Neuroscience|July 25, 2022
Toward Precision Medicine in ADHDJan Buitelaar, Sven Bölte, Daniel Brandeis, et al.
The Lancet. Child & Adolescent Health|April 21, 2020
ADHD management during the COVID-19 pandemic: guidance from the European ADHD Guidelines GroupSamuele Cortese, Philip Asherson, Edmund Sonuga-Barke, et al.
Journal of Attention Disorders|December 17, 2019
Cognition, ADHD Symptoms, and Functional Impairment in Children and Adolescents With Neurofibromatosis Type 1Jonathan M Payne, Kristina M Haebich, Rachel MacKenzie, et al.
European Child & Adolescent Psychiatry|December 17, 2013
Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challengesJeffrey Glennon, Diane Purper-Ouakil, Mireille Bakker, et al.
Molecular Autism|July 2, 2026
Autism in neurofibromatosis type 1: prevalence, phenotype and clinical implicationsJonathan M Payne, Kristina M Haebich, Anita K Chisholm, et al.
Pageof 23